FLOW trial: what semaglutide does for kidney disease in T2D patients

TLDR. The FLOW trial enrolled 3,533 patients with type 2 diabetes and chronic kidney disease, randomized to semaglutide 1.0 mg weekly (the Ozempic dose, not the Wegovy dose) or placebo. The primary kidney composite endpoint was reduced by 24 percent. The trial was stopped early in 2024 for efficacy. KDIGO has updated its guideline to incorporate GLP-1 for T2D with CKD. Insurance coverage now runs through the T2D-plus-CKD pathway rather than the obesity indication. This article reviews what FLOW actually showed, the dosing detail that matters, and what the path to a covered prescription looks like.

FLOW (Effect of Semaglutide on Kidney Outcomes in Patients with T2D and CKD) was published in NEJM in May 2024. It is the most important GLP-1 kidney-disease trial of the decade and underpins recent KDIGO guideline updates incorporating semaglutide into the CKD-with-T2D management algorithm. For patients with kidney disease and their families considering GLP-1, here is the data without the marketing layer.

Trial design

• Population: 3,533 adults with type 2 diabetes AND chronic kidney disease (eGFR 25-75, with albuminuria ≥300 mg/g)
• Intervention: Semaglutide 1.0 mg weekly (the Ozempic dose, not the Wegovy 2.4 mg dose) vs placebo. Both arms continued guideline-directed care including SGLT2 inhibitors and RAAS blockers.
• Primary endpoint: Composite of major kidney-disease events including ≥50% eGFR decline, ESKD requiring kidney replacement therapy, kidney-disease death and cardiovascular death.
• Follow-up: Median 3.4 years.
• Stopped early: Yes, for efficacy. The DSMC recommended stopping at the interim analysis because the benefit was clearly established.

Primary findings

The primary composite endpoint occurred in 18.7% of semaglutide patients vs 23.2% of placebo (HR 0.76, 95% CI 0.66-0.88, p<0.001). That's the 24% relative-risk reduction in the headline.

Number-needed-to-treat to prevent one major kidney event: approximately 22 patients treated for the median 3.4-year follow-up.

Component breakdown

• ≥50% eGFR decline: HR 0.71 (0.55-0.92), significant.
• End-stage kidney disease: HR 0.80 (0.64-1.00), borderline significant.
• Kidney-disease death: HR 0.69 (0.45-1.07), trended positive, did not reach significance.
• Cardiovascular death: HR 0.71 (0.56-0.89), significant.
• All-cause mortality: HR 0.80 (0.67-0.95), significant.
• Major adverse cardiovascular events (MACE secondary endpoint): HR 0.82 (0.68-0.98), significant.

The CV mortality reduction is particularly notable: kidney-disease patients are a high-CV-risk population, and the trial shows semaglutide reduces CV death in this group beyond what SELECT showed in non-T2D CV-disease patients.

Mechanism: why kidney benefit, why now

Three mechanisms appear to drive the kidney effect:

• Glomerular hemodynamics: GLP-1 reduces intraglomerular pressure, similar but smaller magnitude than ACE inhibitors and SGLT2 inhibitors.
• Direct anti-inflammatory effect: GLP-1 receptors are expressed in kidney tissue; receptor activation reduces local inflammation.
• Glucose and weight control: improved A1C and weight loss reduce diabetic-nephropathy progression independently of the direct kidney effects.

The effect appears to be partially independent of weight loss and partially mediated by it. The trial's broader implications: GLP-1 likely complements SGLT2 inhibitors in CKD-T2D management rather than competing with them. Both classes can be used together with stacked benefit.

What FLOW does NOT show

• Primary prevention. FLOW patients all had T2D and established CKD. Whether semaglutide protects kidney function in patients without these conditions is not established.
• Non-T2D CKD. The trial was T2D-specific. Whether semaglutide helps patients with non-diabetic CKD is unstudied.
• Tirzepatide. SURPASS-CVOT is ongoing; FLOW results don't transfer automatically to tirzepatide. Most clinicians treat the kidney benefit as a class effect provisionally, but this is extrapolation.
• End-stage kidney disease on dialysis. FLOW excluded patients on dialysis. Use in ESRD patients is increasingly common in 2026 but is based on case series and small studies, not phase 3 evidence.

The dosing question

FLOW used semaglutide 1.0 mg weekly (the Ozempic dose for T2D), not 2.4 mg (the Wegovy dose for weight loss). For patients with T2D and CKD, the 1.0 mg Ozempic dose is the FLOW-evidence-based dose. For patients with T2D and obesity AND CKD, the higher Wegovy 2.4 mg dose probably provides the kidney benefit too plus additional weight-loss benefit, but the evidence is by extrapolation.

The Medicare/insurance question matters: Ozempic 1.0 mg for T2D is covered with PA at standard Part D and commercial-insurance tiers. Wegovy 2.4 mg without the cardiovascular indication is harder to get covered.

Coverage and access

Most US insurance plans cover Ozempic for T2D at the 1.0 mg dose. KDIGO's 2024 guideline update positioning GLP-1 as part of CKD-T2D management has increased the rate of PA approvals for patients with kidney disease specifically. The PA documentation requires:

• T2D diagnosis (ICD-10 E11.x)
• CKD diagnosis (ICD-10 N18.x) with documented eGFR and albuminuria
• Currently on or contraindicated for an ACE inhibitor or ARB
• Often: SGLT2 inhibitor first or concurrently

See our best-for-Medicare-T2D rankings and /best/aetna/ for the programs that handle this PA correctly.

Programs equipped for CKD-T2D management

9amHealth specifically targets cardiometabolic patients including those with CKD; their clinical model includes the labs and coordination kidney patients need. Form Health handles complex comorbidities and writes PA appropriately. Knownwell's primary-care model integrates nephrology coordination as part of standard workup.

Cash-pay compounded programs are not appropriate for CKD patients without nephrology involvement; the FLOW dose is 1.0 mg, the medication choice should be evidence-based brand or insurance-pathway and the kidney monitoring requires real lab integration.

For the SELECT cardiovascular-indication parallel, see our SELECT MACE deep-dive. For other kidney-disease-relevant patient considerations, see our honest-risks article which covers the renal dose-adjustment question.

Frequently asked questions

What is the FLOW trial?

A 3,533-patient randomized trial of semaglutide 1.0 mg weekly versus placebo in patients with type 2 diabetes and chronic kidney disease. The primary endpoint was a composite of kidney failure events, sustained decline in eGFR, kidney death, or cardiovascular death. Published in NEJM 2024 after the trial was stopped early for efficacy.

What did FLOW show?

Semaglutide reduced the primary kidney composite endpoint by 24 percent versus placebo (hazard ratio 0.76, 95% CI 0.66 to 0.88). The cardiovascular death component of the endpoint also showed benefit. The trial was stopped early in 2024 when the data and safety monitoring board judged the efficacy threshold met.

Does FLOW apply to Wegovy?

Indirectly. The FLOW dose is semaglutide 1.0 mg weekly, which is the Ozempic maximum, not the Wegovy maximum (2.4 mg). Wegovy contains the same molecule at a higher dose, and the directional effect is likely similar, but the FLOW evidence is specific to the 1.0 mg dose. Coverage and prescribing run through the Ozempic label.

Did KDIGO change its guideline based on FLOW?

Yes. The 2024 KDIGO update incorporates GLP-1 receptor agonists (specifically semaglutide based on FLOW) for patients with T2D and CKD as part of standard cardiorenal protection alongside SGLT2 inhibitors and RAS blockade. Nephrology practice is moving toward GLP-1 as a routine consideration for this population.

How does coverage work for GLP-1 in T2D + CKD?

Through the T2D plus CKD pathway, not the obesity indication. Most commercial plans and Medicare Part D cover Ozempic for T2D under standard PA criteria, with CKD as a supporting comorbidity that strengthens the case. The prescribing diagnosis is type 2 diabetes; the kidney indication informs the clinical rationale but the label is T2D.